跳转至内容
Merck
CN

M2523

Supelco

甲苯咪唑

analytical standard, ≥98% (HPLC)

登录查看公司和协议定价

别名:
5-苯甲酰-2-苯并咪唑胺甲酸甲酯, 甲基N-(5-苯甲酰基-1H-苯并咪唑-2-基)氨基甲酸酯, 甲苯咪唑
经验公式(希尔记法):
C16H13N3O3
CAS号:
分子量:
295.29
Beilstein:
759809
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

analytical standard

质量水平

检测方案

≥98% (HPLC)

技术

HPLC: suitable
gas chromatography (GC): suitable

应用

forensics and toxicology
pharmaceutical (small molecule)

格式

neat

SMILES字符串

COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c3ccccc3

InChI

1S/C16H13N3O3/c1-22-16(21)19-15-17-12-8-7-11(9-13(12)18-15)14(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,17,18,19,21)

InChI key

OPXLLQIJSORQAM-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

甲苯咪唑是一种苯并咪唑氨基甲酸酯衍生物,可作为驱虫药。

应用

有关合适仪器技术的更多信息,请参考产品分析证书。如需进一步支持,请联系技术服务。

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Acute Tox. 4 Oral

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Gloves


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

The Antimicrobial Drugs (2000)
Peter Nygren et al.
Journal of cancer research and clinical oncology, 139(12), 2133-2140 (2013-10-19)
In the present study, we screened a compound library containing 1,600 clinically used compounds with the aim to identify compounds, which potentially could be repositioned for colon cancer therapy. Two established colon cancer cell lines were tested using the fluorometric
Sara Carlert et al.
Molecular pharmaceutics, 9(10), 2903-2911 (2012-09-08)
The purpose of this study was to investigate in vivo intestinal precipitation of a model drug mebendazole, a basic BCS class II drug, using dogs with intestinal stomas for administration or sampling. After oral administration of a solution with an
Monica Longo et al.
Reproductive toxicology (Elmsford, N.Y.), 36, 78-87 (2013-01-05)
Filarial diseases affect millions of people in poverty-stricken areas. In 2011, an investigation of the potential of flubendazole as a safe, highly efficacious, and field-usable macrofilaricidal drug was begun by Drug for Neglected Diseases initiative. As part of the preclinical
Sivanesan Dakshanamurthy et al.
Journal of medicinal chemistry, 55(15), 6832-6848 (2012-07-12)
The most effective way to move from target identification to the clinic is to identify already approved drugs with the potential for activating or inhibiting unintended targets (repurposing or repositioning). This is usually achieved by high throughput chemical screening, transcriptome

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门